Wuhan YZY Biopharma
YZY Biopharma is a Wuhan company listed in Hong Kong that builds bispecific antibodies, including one given directly into the abdomen to control fluid build-up from cancer.
Overview
Wuhan YZY Biopharma, founded in 2010 and listed in Hong Kong, develops bispecific antibodies on its YBODY platform. Its lead product M701, an EpCAM and CD3 bispecific given intraperitoneally for malignant ascites, and M802, a HER2 and CD3 bispecific, are in trials in China, with the ascites programme in phase 3 registered on ClinicalTrials.gov under YZY as lead sponsor.
Similar pages
not linked directly; found by shared links- CompanyHarbour BioMed
Shares Bispecific antibodies, Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyCSL Limited
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyD3 Bio (Wuxi)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyDong-A ST
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEndo (now Keenova Therapeutics and Par Health)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEurofarma
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyGrifols
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyInsys Therapeutics
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.